These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 18489993)

  • 1. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
    Andersson BS; de Lima M; Thall PF; Wang X; Couriel D; Korbling M; Roberson S; Giralt S; Pierre B; Russell JA; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):672-84. PubMed ID: 18489993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
    Andersson BS; de Lima M; Thall PF; Madden T; Russell JA; Champlin RE
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1(Suppl 1):S11-5. PubMed ID: 19561406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
    Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
    Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unrelated donor transplantation for acute myelogenous leukemia in first remission.
    Bashir Q; Andersson BS; Fernandez-Vina M; de Padua Silva L; Giralt S; Chiattone A; Wei W; Sharma M; Anderlini P; Shpall EJ; Popat U; Rodrigues M; Champlin RE; de Lima M
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1067-71. PubMed ID: 21087679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
    Alatrash G; de Lima M; Hamerschlak N; Pelosini M; Wang X; Xiao L; Kerbauy F; Chiattone A; Rondon G; Qazilbash MH; Giralt SA; de Padua Silva L; Hosing C; Kebriaei P; Zhang W; Nieto Y; Saliba RM; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1490-6. PubMed ID: 21338705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
    Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
    de Lima M; Couriel D; Thall PF; Wang X; Madden T; Jones R; Shpall EJ; Shahjahan M; Pierre B; Giralt S; Korbling M; Russell JA; Champlin RE; Andersson BS
    Blood; 2004 Aug; 104(3):857-64. PubMed ID: 15073038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.
    DiMaggio E; Zhou JM; Caddell R; Tombleson R; Perkins J; Anasetti C; Khimani F; Pidala J; Nishihori T; Perez L; Betts B; Fernandez HF; Mishra A
    Leuk Lymphoma; 2020 Jul; 61(7):1678-1687. PubMed ID: 32133897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
    Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
    Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.